NEW YORK, March 19, 2018 -- ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and marketing of OTC healthcare products, is pleased to announce the launch of the INR Wellness immune support product line.
INR Wellness is a once-daily nutritional supplement that contains yeast, oat, and mushroom beta-glucans. These three naturally occurring beta-glucans have been shown across hundreds of clinical studies to support the human immune system and are commonly used as an OTC supplement to reduce cholesterol levels, manage blood glucose levels, and to support the immune system in people whose body defenses have been weakened by conditions such as chronic fatigue, or physical and emotional stress; or by treatments such as radiation or chemotherapy.
Immudyne’s INR Wellness product is the first in the world with a proprietary triple-action formulation that contains what we believe to be the most important beta glucans for overall immune support.
“We’re excited to add another revenue stream to Immudyne’s portfolio,” stated Justin Schreiber, President & CEO of Immudyne. “We believe INR Wellness is the highest quality immune support product on the market and presents a significant growth opportunity for the Company.”
Immudyne will begin sales of INR Wellness on Monday, March 19th, 2018 through the Company’s website. A national Facebook, Google and Amazon campaign will commence shortly thereafter.
“In 2017, the U.S. nutritional supplement and vitamin market was approximately $36.1 billion,” stated Stefan Galluppi, Chief Technology and Operating Officer of Immudyne. “The immune support vertical is an attractive segment of the supplement market that has seen little innovation in recent years. Given the extensive clinical data and proprietary formulation of INR Wellness, we believe we're well positioned for a successful product launch.”
For more information on INR Wellness or to purchase the product, please visit https://www.inrwellness.com/.
About lmmuDyne
lmmuDyne, Inc. (the "Company") is an online direct response marketing company that builds innovative and proprietary health and wellness brands that transform and enrich the lives of consumers around the world. Immudyne’s scalable and global advertising technology infrastructure leverages the world’s largest social media and online sales platforms (Facebook, Google & Amazon) to rapidly and profitably grow our continually expanding product portfolio. To learn more about our corporate strategy, brands or for investor relations please visit www.immudyne.com or email us at [email protected].


Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Jetstar to Charge for Overhead Cabin Bags From February
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 



